Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP

References

• Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch F, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38. doi:10.1186/1750-9378-7-38.
   PubMed Web of Science ®Google Scholar
• Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H-K, Chow LT, Huh WK, et al. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol. 2013;87(11):6127–36. doi:10.1128/JVI.03218-12.
   PubMed Web of Science ®Google Scholar
• Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000;270(2):254–57. doi:10.1006/viro.2000.0272.
   PubMed Web of Science ®Google Scholar
• Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol. 1996;70(9):5875–83. doi:10.1128/JVI.70.9.5875-5883.1996.
   PubMed Web of Science ®Google Scholar
• Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5(3):557–67. doi:10.1016/S1097-2765(00)80449-9.
   PubMed Web of Science ®Google Scholar
• El Aliani A, El Abid H, Kassal Y, Khyatti M, Attaleb M, Ennaji MM, El Mzibri M. HPV16 L1 diversity and its potential impact on the vaccination-induced immunity. Gene. 2020;747:144682. doi:10.1016/j.gene.2020.144682.
   PubMed Web of Science ®Google Scholar
• Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RBS, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol. 2007;81(24):13927–31. doi:10.1128/JVI.00936-07.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu H, Zhang T, Liu Y, Xie X, Wang Z, Xu X. A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One. 2014;9(5):e95448. doi:10.1371/journal.pone.0095448.
   PubMed Web of Science ®Google Scholar
• Motavalli Khiavi F, Arashkia A, Golkar M, Nasimi M, Roohvand F, Azadmanesh K. A dual-type L2 11-88 peptide from HPV types 16/18 formulated in montanide ISA 720 induced strong and balanced Th1/Th2 immune responses, associated with high titers of broad spectrum cross-reactive antibodies in vaccinated mice. J Immunol Res. 2018;2018:9464186. doi:10.1155/2018/9464186.
   PubMed Web of Science ®Google Scholar
• Vujadinovic M, Khan S, Oosterhuis K, Uil TG, Wunderlich K, Damman S, Boedhoe S, Verwilligen A, Knibbe J, Serroyen J, et al. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. Vaccine. 2018;36(30):4462–70. doi:10.1016/j.vaccine.2018.06.024.
   PubMed Web of Science ®Google Scholar
• Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M, et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One. 2012;7(6):e39741. doi:10.1371/journal.pone.0039741.
   PubMed Web of Science ®Google Scholar
• Jiang RT, Schellenbacher C, Chackerian B, Roden RBS. Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines. 2016;15(7):853–62. doi:10.1586/14760584.2016.1157479.
   PubMed Web of Science ®Google Scholar
• Olczak P, Roden RBS. Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases. Vaccines (Basel). 2020;8(4). doi:10.3390/vaccines8040568.
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol. 2009;83(19):10085–95. doi:10.1128/JVI.01088-09.
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013;133(12):2706–13. doi:10.1038/jid.2013.253.
   PubMed Web of Science ®Google Scholar
• Powell BS, Andrianov AK, Fusco PC. Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res. 2015;4(1):23–45. doi:10.7774/cevr.2015.4.1.23.
   PubMed Web of Science ®Google Scholar
• Andrianov AK. Polyphosphazenes as vaccine adjuvants. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken (New Jersey): John Wiley & Sons; 2007. p. 355–78.
   Google Scholar
• Magiri R, Mutwiri G, Wilson HL. Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action. Cell Tissue Res. 2018;374(3):465–71. doi:10.1007/s00441-018-2929-4.
   PubMed Web of Science ®Google Scholar
• Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, Johansen K. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine. 2008;26(35):4594–601. doi:10.1016/j.vaccine.2008.05.089.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Fuerst TR. Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation. Biomacromolecules. 2016;17(11):3732–42. doi:10.1021/acs.biomac.6b01251.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Roberts BE. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules. 2005;6(3):1375–79. doi:10.1021/bm049329t.
   PubMed Web of Science ®Google Scholar
• Cayatte C, Marin A, Rajani GM, Schneider-Ohrum K, Snell Bennett A, Marshall JD, Andrianov AK. PCPP-adjuvanted Respiratory Syncytial Virus (RSV) sF subunit vaccine: self-assembled supramolecular complexes enable enhanced immunogenicity and protection. Mol Pharm. 2017;14(7):2285–93. doi:10.1021/acs.molpharmaceut.7b00118.
   PubMedGoogle Scholar
• Andrianov AK, Marin A, Wang R, Chowdhury A, Agnihotri P, Yunus AS, Pierce BG, Mariuzza RA, Fuerst TR. In vivo and in vitro potency of polyphosphazene immunoadjuvants with hepatitis C virus antigen and the role of their supramolecular assembly. Mol Pharm. 2020. doi:10.1021/acs.molpharmaceut.0c00487.
   PubMedGoogle Scholar
• Andrianov AK, Svirkin YY, LeGolvan MP. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules. 2004;5(5):1999–2006. doi:10.1021/bm049745d.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Chen J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules. 2006;7(1):394–99. doi:10.1021/bm050790a.
   PubMed Web of Science ®Google Scholar
• Wang JW, Matsui K, Pan Y, Kwak K, Peng S, Kemp T, Pinto L, Roden RB. Production of furin-cleaved papillomavirus pseudovirions and their use for in vitro neutralization assays of L1- or L2-specific antibodies. Curr Protoc Microbiol. 2015;38:14B 5 1–26.
   PubMedGoogle Scholar
• Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RBS. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology. 2014;449:304–16. doi:10.1016/j.virol.2013.10.038.
   PubMed Web of Science ®Google Scholar
• Yessine MA, Leroux JC. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv Drug Deliv Rev. 2004;56(7):999–1021. doi:10.1016/j.addr.2003.10.039.
   PubMed Web of Science ®Google Scholar
• Lackey CA, Murthy N, Press OW, Tirrell DA, Hoffman AS, Stayton PS. Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates †. Bioconjug Chem. 1999;10(3):401–05. doi:10.1021/bc980109k.
   PubMed Web of Science ®Google Scholar
• Rozema DB, Ekena K, Lewis DL, Loomis AG, Wolff JA. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconjug Chem. 2003;14(1):51–57. doi:10.1021/bc0255945.
   PubMed Web of Science ®Google Scholar
• Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D´Oro U, Casini D, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep. 2016;6:19570. doi:10.1038/srep19570.
   PubMed Web of Science ®Google Scholar
• Palmer CD, Ninković J, Prokopowicz ZM, Mancuso CJ, Marin A, Andrianov AK, Dowling DJ, Levy O. The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells. Biomaterials. 2014;35(31):8876–86. doi:10.1016/j.biomaterials.2014.06.043.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Fuerst TR. Self-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity. Heliyon. 2016;2(4):e00102. doi:10.1016/j.heliyon.2016.e00102.
   PubMed Web of Science ®Google Scholar
• Awate S, Wilson HL, Lai K, Babiuk LA, Mutwiri G. Activation of adjuvant core response genes by the novel adjuvant PCEP. Mol Immunol. 2012;51(3–4):292–303. doi:10.1016/j.molimm.2012.03.026.
   PubMed Web of Science ®Google Scholar
• Awate S, Wilson HL, Singh B, Babiuk LA, Mutwiri G. The adjuvant PCEP induces recruitment of myeloid and lymphoid cells at the injection site and draining lymph node. Vaccine. 2014;32(21):2420–27. doi:10.1016/j.vaccine.2014.03.014.
   PubMed Web of Science ®Google Scholar
• Mutwiri G, Benjamin P, Soita H, Babiuk LA. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine. 2008;26(22):2680–88. doi:10.1016/j.vaccine.2008.03.031.
   PubMed Web of Science ®Google Scholar
• Garlapati S, Eng NF, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock REW, Halperin SA, Potter AA, Babiuk LA, Gerdts V, et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine. 2011;29(38):6540–48. doi:10.1016/j.vaccine.2011.07.009.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Wang R, Karauzum H, Chowdhury A, Agnihotri P, Yunus AS, Mariuzza RA, Fuerst TR. Supramolecular assembly of toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo. ACS Appl Bio Mater. 2020;3(5):3187–95. doi:10.1021/acsabm.0c00189.
   PubMedGoogle Scholar
• Andrianov AK, Le Golvan MP. Characterization of poly [di (carboxylatophenoxy)‐phosphazene] by an aqueous gel permeation chromatography. J Appl Polym Sci. 1996;60(12):2289–95. doi:10.1002/(SICI)1097-4628(19960620)60:12<2289::AID-APP28>3.0.CO;2-0.
   Web of Science ®Google Scholar
• Andrianov AK. Self-assembling ionic polyphosphazenes and their biomedical applications. In: Andrianov AK, Allcock HR, editors. Polyphosphazenes in biomedicine, engineering, and pioneering synthesis. ACS Symposium Series. Vol. 1298.Washington, DC: American Chemical Society; 2018. p. 27–49. doi:10.1021/bk-2018-1298.ch002
   Google Scholar
• Andrianov AK, Marin A, Deng J, Fuerst TR. Protein-loaded soluble and nanoparticulate formulations of ionic polyphosphazenes and their interactions on molecular and cellular levels. Mater Sci Eng C Mater Biol Appl. 2020;106:110179. doi:10.1016/j.msec.2019.110179.
   PubMed Web of Science ®Google Scholar
• Selin V, Albright V, Ankner JF, Marin A, Andrianov AK, Sukhishvili SA. Biocompatible nanocoatings of fluorinated polyphosphazenes through aqueous assembly. ACS Appl Mater Interfaces. 2018;10(11):9756–64. doi:10.1021/acsami.8b02072.
   PubMed Web of Science ®Google Scholar
• Albright V, Marin A, Kaner P, Sukhishvili SA, Andrianov AK. New family of water-soluble sulfo–fluoro polyphosphazenes and their assembly within hemocompatible nanocoatings. ACS Appl Bio Mater. 2019;2(9):3897–906. doi:10.1021/acsabm.9b00485.
   PubMedGoogle Scholar
• Manzenrieder F, Luxenhofer R, Retzlaff M, Jordan R, Finn MG. Stabilization of virus‐like particles with poly (2‐oxazoline) s. Angewandte Chem. 2011;123(11):2649–53. doi:10.1002/ange.201006134.
   Google Scholar
• Lee PW, Isarov SA, Wallat JD, Molugu SK, Shukla S, Sun JEP, Zhang J, Zheng Y, Lucius Dougherty M, Konkolewicz D, et al. Polymer structure and conformation alter the antigenicity of virus-like particle-polymer conjugates. J Am Chem Soc. 2017;139(9):3312–15. doi:10.1021/jacs.6b11643.
   PubMed Web of Science ®Google Scholar
• Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine. 2007;25(7):1204–13. doi:10.1016/j.vaccine.2006.10.011.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Chen J, Payne LG. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials. 1998;19(1–3):109–15. doi:10.1016/S0142-9612(97)00227-5.
   PubMed Web of Science ®Google Scholar
• Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88. doi:10.1111/j.1365-2567.2005.02268.x.
   PubMed Web of Science ®Google Scholar
• Stier EM, Mandal M, Lee KD. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm. 2005;2(1):74–82. doi:10.1021/mp049896v.
   PubMedGoogle Scholar
• Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008;86(4):353–62. doi:10.1038/icb.2008.3.
   PubMed Web of Science ®Google Scholar
• Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003;63:3478–82.
   PubMed Web of Science ®Google Scholar
• Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406. doi:10.3389/fimmu.2012.00406.
   PubMed Web of Science ®Google Scholar
• Hjelholt A, Christiansen G, Sørensen US, Birkelund S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog Dis. 2013;67(3):206–13. doi:10.1111/2049-632X.12034.
   PubMed Web of Science ®Google Scholar
• Aalberse RC, Platts-Mills TA, Rispens T. The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response. Curr Allergy Asthma Rep. 2016;16(6):45. doi:10.1007/s11882-016-0621-x.
   PubMed Web of Science ®Google Scholar
• Spazierer D, Skvara H, Dawid M, Fallahi N, Gruber K, Rose K, Lloyd P, Heuerding S, Stingl G, Jung T, et al. T helper 2 biased de novo immune response to keyhole limpet hemocyanin in humans. Clin Exp Allergy. 2009;39(7):999–1008. doi:10.1111/j.1365-2222.2008.03177.x.
   PubMed Web of Science ®Google Scholar
• Terhune TD, Deth RC. Aluminum adjuvant-containing vaccines in the context of the hygiene hypothesis: a risk factor for eosinophilia and allergy in a genetically susceptible subpopulation? Int J Environ Res Public Health. 2018;15(5):901. doi:10.3390/ijerph15050901.
   PubMed Web of Science ®Google Scholar
• Eng NF, Garlapati S, Gerdts V, Babiuk LA, Mutwiri GK. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. J Immune Based Ther Vaccines. 2010;8:4. doi:10.1186/1476-8518-8-4.
   PubMedGoogle Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi:10.3389/fimmu.2013.00114.
   PubMed Web of Science ®Google Scholar
• Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, Tommasino M, Ottonello S, Müller M. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology. 2011;409(2):348–59. doi:10.1016/j.virol.2010.10.017.
   PubMed Web of Science ®Google Scholar
• Wang JW, Wu WH, Huang T-C, Wong M, Kwak K, Ozato K, Hung C-F, Roden RBS. Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus. J Virol. 2018;92(15). doi:10.1128/JVI.00572-18.
   Web of Science ®Google Scholar
• Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL, et al. Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles. J Virol. 2016;90(14):6314–25. doi:10.1128/JVI.00449-16.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Decollibus DP, Marin A, Webb A, Griffin Y, Webby RJ. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. J Pharm Sci. 2011;100(4):1436–43. doi:10.1002/jps.22367.
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW. Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm. 2015;94:220–28. doi:10.1016/j.ejpb.2015.05.009.
   PubMed Web of Science ®Google Scholar